In Q3'26, total operating expenses for AFRM reached $218M, comprising $0 in R&D expenses and $218M in SG&A expenses, reflecting a notable absence of R&D spending amid ongoing cost management efforts. From Q4'23 to Q2'26, R&D expenses exhibited an overall upward trend, starting at $152M and climbing to $185M, with a brief decline in Q1'24 to Q2'24 before steady growth resumed; meanwhile, SG&A expenses showed volatility, peaking at $294M in Q2'24, dipping to $208M in Q3'25, and recovering to $240M in Q2'26, resulting in total operating expenses fluctuating between $425M and $579M before the Q3'26 drop due to missing R&D data. This stacked bar chart highlights a general increase in operating costs driven by R&D expansion, though SG&A's fluctuations suggest operational adjustments, warranting monitoring for efficiency in future quarters.